Drug Combination Details
| General Information of the Combination (ID: C00848) | |||||
|---|---|---|---|---|---|
| Name | Osthole NP Info | + | Trastuzumab Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Stomach cancer
[ICD-11: 2B72]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-N87 | CVCL_1603 | Gastric tubular adenocarcinoma | Homo sapiens | ||
| In-vivo Model | N87 cells (1*107/per mouse) were inoculated subcutaneously into the right flank of female BALB/c nude mice. | |||||
| Experimental
Result(s) |
Osthole synergizes with trastuzumab in HER2-overexpressed N87 gastric cancer by inducing apoptosis and inhibition of AKT-MAPK pathway. | |||||
